The latest update is out from Reviva Pharmaceuticals Holdings (RVPH).
Reviva Pharmaceuticals Holdings, Inc. has announced a significant step forward in the development of its schizophrenia treatment, brilaroxazine, with the FDA’s acceptance of its Phase 3 program. The company’s alignment with FDA expectations puts it on track to begin the RECOVER-2 trial, aiming to demonstrate the drug’s efficacy and safety in managing acute schizophrenia symptoms. Positive results from two pivotal trials and a year of safety data could lead to a New Drug Application (NDA) submission by the third quarter of 2025, marking a promising development for patients and investors alike.
Find detailed analytics on RVPH stock on TipRanks’ Stock Analysis page.
